Medizinische Universität Innsbruck
Welcome,         Profile    Billing    Logout  
 144 Trials 
833 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hintringer, Florian
NCT03818724: Treatment Success With the CoolLoop Cryoablation System

Recruiting
N/A
540
Europe
CoolLoop® cryoablation system
afreeze GmbH, Raffeiner GmbH
Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Arrhythmias, Cardiac, Cardiovascular Diseases, Heart Diseases
01/25
01/25
Karall, Daniela
NCT05554835: Global Registry and Natural History Study for Mitochondrial Disorders

Recruiting
N/A
6000
Europe
LMU Klinikum, European Commission, German Federal Ministry of Education and Research, University of Pisa
Mitochondrial Diseases, Kearns-Sayre Syndrome, MIDD, SANDO, SCAE, NARP Syndrome, MELAS Syndrome, MERRF Syndrome, Coenzyme Q10 Deficiency, LHON, MNGIE, MIRAS, Barth Syndrome, MDS, Mitochondrial Myopathies, Leigh Syndrome, Pearson Syndrome, CPEO
12/40
12/40
Koch, Robert
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/24
03/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Reinstadler, Sebastian Johannes
NCT04939805: CRP Apheresis in STEMI

Recruiting
N/A
202
Europe
Selective CRP apheresis using the PentraSorb®-CRP system
Medical University Innsbruck
ST Elevation Myocardial Infarction, C-Reactive Protein, Apheresis, Myocardial Injury
03/24
03/25
RIP-HIGH, NCT04844931: Remote Ischemic Conditioning With Local Ischemic Postconditioning in High-Risk ST-elevation Myocardial Infarction

Recruiting
N/A
250
Europe
RIC + PostC + Standard PCI, Standard PCI
Helios Health Institute GmbH, Heart Center Leipzig - University Hospital
ST Elevation Myocardial Infarction
05/26
12/30
MARINA-STEMI, NCT04113356: Magnetic Resonance Imaging In Acute ST-Elevation Myocardial Infarction

Recruiting
N/A
1500
Europe
Cardiovascular Magnetic Resonance Imaging
Medical University Innsbruck
Acute ST-Elevation Myocardial Infarction
06/26
06/31
Streif, Werner
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
Martini, Judith
NCT05077124: Safe and Timely Antithrombotic Removal (STAR) Registry

Recruiting
N/A
500
Europe
CytoSorb
CytoSorbents, Inc
Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
09/25
09/25
Implement-PMI, NCT05859620: Implementation of a Clinical Screening and Response System for Cardiac Complications After Noncardiac Surgery

Recruiting
N/A
900
Europe
Patient assessment and follow-up
University Hospital, Basel, Switzerland, Luzerner Kantonsspital, Kantonsspital Olten, Medical University Innsbruck, University Hospital, Geneva, Bürgerspital Solothurn
Myocardial Injury, Myocardial Infarction, Perioperative Complication
12/25
12/25
Kronberger, Irmgard
MiFlaPRO, NCT04335617 / 2019-001916-44: Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis

Recruiting
3
200
Europe
MMPF (Micronized purified Flavonoid-Fraction), Placebo
Medical University Innsbruck, Servier Affaires Médicales
Proctitis Radiation
02/23
08/23
Plank, Graziella
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
Colipris, NCT04095351: Connective Tissue Diseases and Lung Manifestations

Recruiting
N/A
120
Europe
Pulmonary function test, Imaging, Blood sampling
Medical University Innsbruck, Boehringer Ingelheim
Connective Tissue Diseases, Interstitial Lung Disease, Systemic Sclerosis
03/21
10/34
Diaz, Rosa
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
He, Chiyi
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Recruiting
3
408
RoW
Vedolizumab IV, Placebo
Takeda
Crohn's Disease
03/30
05/31
Seeber, Andreas
NCT03301493: Genomic Testing and Resulting Medical Decisions

Recruiting
N/A
1000
Europe
Genomic testing
Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, AstraZeneca
Cancer of Unknown Origin, Cancer Refractory, Cancer of Stomach, Cancer Head Neck, Cancer of Skin, Cancer, Lung, Cancer Colorectal, Cancer of Esophagus, Cancer, Bladder, Cancer, Uterus, Cancer Cervix, Cancer Liver, Cancer, Kidney, Cancer, Breast, Hematologic Neoplasms
12/24
12/24
SOUND, NCT05032092: Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Carcinoma

Recruiting
N/A
200
Europe
Next Generation Sequencing, FoundationOne®Liquid CDx, FoundationOne® CDx, Biomarker Monitoring, AVENIO ctDNA Surveillance Kit
Medical University of Graz
Locally Advanced Carcinoma, Metastatic Cancer
04/24
07/24
Steidl, Karin
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
Piringer, Peter
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
Nelles, Philipp
SpeCY, NCT05946512: MR-spectroscopy in Post-covid Condition Prior to and Following a Yoga Breathing Intervention

Recruiting
N/A
320
Europe
yoga, social contact
Medical University Innsbruck
Post COVID-19 Condition, Somatic Symptom Disorder
07/26
01/27
Rudzki, Jakob
ARES, NCT04769895: MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

Recruiting
3
75
Europe
MaaT013
MaaT Pharma
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
09/23
09/24
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
Pohl, Silke
COMBAT_T2_NASH, NCT04639414: Combined Active Treatment in Type 2 Diabetes With NASH

Recruiting
4
192
Europe
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo
The Deutsche Diabetes Forschungsgesellschaft e.V., Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
01/25
12/25
Blaisure, Haley
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
Beale, Alex
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
 

Download Options